Foundation Medicine Launches FoundationOne Liquid Cancer Biopsy Test

– FoundationOne Liquid analyzes 70 genes known to drive cancer growth and reports microsatellite instability high (MSI-high) status to inform the use of precision oncology treatments, including immunotherapies, with a simple blood draw –

 Foundation Medicine, Inc. today announced that FoundationOne^®Liquid, its next-generation liquid biopsy test for solid tumors, is commercially available in the United States. Using a blood sample, FoundationOne Liquid analyzes 70 genes known to drive cancer growth, including homologous recombination deficiency (HRD) genes, and reports the genomic biomarker for microsatellite instability (MSI),¹ to help inform the use of checkpoint inhibitor immunotherapies and multiple targeted therapies, including poly (ADP-ribose) polymerase (PARP) inhibitors, as well as clinical trials for patients with advanced cancer.

“With the commercial launch of FoundationOne Liquid, we are further expanding access to important genomic information that has the potential to match more patients to targeted therapies,” said Tom Civik, Chief Commercial Officer at Foundation Medicine. “For many cancer patients, traditional tissue testing is not feasible, and there is a pressing need for minimally invasive solutions to help inform personalized treatment decisions. FoundationOne Liquid meets our highest standards for sensitivity and analytical validation and offers providers additional insights to help guide treatment options, including immunotherapies and PARP inhibitors. In addition to the clinical advancements this test provides, it will also help our biopharma partners improve trial design and accelerate drug development.”

FoundationOne Liquid is a hybrid capture-based, next-generation sequencing in vitro diagnostic device for the detection of substitutions, insertion and deletion alterations (indels), copy number alterations (CNAs) and select gene rearrangements using circulating cell-free DNA (cfDNA) isolated from plasma derived from peripheral whole blood. The FoundationOne Liquid test expands upon the previous version of the Company’s liquid biopsy test, FoundationACT^®, which has been analytically validated across the four main classes of genomic alterations. Evaluation of the platform using multiple validation methods across a broad range of tumor types demonstrated high sensitivity² and positive predictive value³, even at the low allele frequencies often observed in clinical samples.⁴

https://www.biospace.com/article/releases/foundation-medicine-introduces-foundationone-liquid-the-latest-advance-in-the-company-s-liquid-biopsy-test-for-solid-tumors-in-patients-with-advanced-cancer/